Post Profile






Georgetown Receives FDA Clearance to Conduct Clinical Trial with Nilotinib in Alzheimer's Disease

Georgetown University Medical Center today announces the U.S. Food and Drug Administration has completed its review of an investigational new drug application (IND) for the use of nilotinib in a phase II clinical trial for patients with mild to moderate Alzheimer's disease.
read more

share

Related Posts


Novagali Pharma Announces FDA Clearance Of IND For Phase III Of Catioprost(R), Its Cationic Emulsion Of Latanoprost In Patients With Glaucoma

Health : Medical News Today

Novagali Pharma, a French pharmaceutical ophthalmic company, announces that the Company's Investigational New Drug Application (IND) to conduct a Phase III clinical trial of Catioprost(R) (Nova21027), for the treatment of glaucoma h...

Cornerstone Pharmaceuticals Announces Approval To Conduct Phase I/II Clinical Trial Of CPI-613 In Cancer Patients By US FDA

Health : Medical News Today

Cornerstone Pharmaceuticals, Inc., a privately held pharmaceutical company, announced today that it has received clearance from the US Food and Drug Administration (FDA) to begin a Phase I/II clinical trial evaluating the safety and...

Immunovaccine Receives Clearance From FDA To Proceed With Phase 1 Clinical Trial For Its Therapeutic Cancer Vaccine

Health : Medical News Today

Immunovaccine Inc. (TSX VENTURE:IMV) announced that its Investigational New Drug (IND) application for its therapeutic cancer vaccine, DPX-0907, has been cleared by the U.S. Food and Drug Administration (FDA). DPX-0907 is Immunovacc...

New Clinical Trial Will Test Cancer Drug as Alzheimer's Treatment

Health : Newswise Medical News

The Alzheimer's Drug Discovery Foundation (ADDF) announces a $2.1 million grant awarded to R. Scott Turner, MD, PhD, of Georgetown University Medical Center to conduct a phase II clinical trial of low-dose nilotinib (marketed as Tas...

U.S. Naval Medical Research Center Resubmits IND Application For Proposed 'RESUS' Clinical Trial In Trauma Patients In The Out-of-Hospital Setting

Health : Medical News Today

Biopure Corporation (Nasdaq: BPUR) announced that the U.S. Naval Medical Research Center (NMRC) has submitted to the Food and Drug Administration (FDA) a revised investigational new drug (IND) application to conduct a clinical trial...

Comments


Copyright © 2016 Regator, LLC